Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …

Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Background The efficacy of ceftazidime-avibactam—a cephalosporin–β-lactamase inhibitor
combination with in vitro activity against Klebsiella pneumoniae carbapenemase–producing …

Methods A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-
acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection …

Background A growing body of observational evidence supports the value of ceftazidime-
avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant …

Carbapenem-resistant Enterobacteriaceae (CRE) infection is highly endemic in China, but
estimates of the infection burden are lacking. We established the incidence of CRE infection …

Abstract Background Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for
the treatment of complicated intra-abdominal and urinary tract infections, as well as hospital …

This study quantified mortality associated with serious infections caused by carbapenem-
resistant (CRE) and carbapenem-susceptible Enterobacteriaceae (CSE). A systematic …

Introduction: Management of antimicrobial resistance in multi-drug-resistant-Klebsiella
pneumoniae (MDR-KP) is a major challenge for clinicians. The optimal treatment option for …

ABSTRACT Although the New York/New Jersey (NY/NJ) area is an epicenter for
carbapenem-resistant Enterobacteriaceae (CRE), there are few multicenter studies of CRE …